Comments on: Clinical effectiveness and safety of razumab (A biosimilar of ranibizumab)

Comments on: Clinical effectiveness and safety of razumab (A biosimilar of ranibizumab)

Bibliographic Details
Main Author:	Mithun Thulasidas
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2022-01-01
Series:	TNOA Journal of Ophthalmic Science and Research
Online Access:	http://www.tnoajosr.com/article.asp?issn=2589-4528;year=2022;volume=60;issue=1;spage=133;epage=133;aulast=Thulasidas

Similar Items

Clinical effectiveness and safety of razumab (a biosimilar of ranibizumab)
by: Sriram Gopal, et al.
Published: (2020-01-01)

Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
by: Lalit Verma, et al.
Published: (2021-01-01)

Safety and efficacy of Razumab – The new biosimilar in India: Our experience
by: V V Sameera, et al.
Published: (2016-01-01)

A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion
by: Shashikant Sharma, et al.
Published: (2020-07-01)

Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study
by: Shashikant Sharma, et al.
Published: (2021-03-01)

Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?
by: Chatzimichail E, et al.
Published: (2024-02-01)

Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment
by: Netan Choudhry, et al.
Published: (2023-10-01)

Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity
by: Vipul Prajapati, et al.
Published: (2023-01-01)

Comments on: Comparative study of secondary implantation of iris–claw lens and scleral-fixated intraocular lens in terms of visual outcome and complications
by: Mithun Thulasidas
Published: (2022-01-01)

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
by: Yasuo Yanagi, et al.
Published: (2023-05-01)

Comments on: Validating tablet perimetry against standard Humphrey Visual Field Analyzer for glaucoma screening in Indian population
by: Harsh Kumar, et al.
Published: (2021-01-01)

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
by: Yasuo Yanagi, et al.
Published: (2023-08-01)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
by: João Pedro Fernandes, et al.
Published: (2015-03-01)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
by: João Pedro Fernandes, et al.
Published: (2015-01-01)

Reply to comments on: Retropupillary iris-claw intraocular lens implantation in aphakic patients
by: C V Sumitha, et al.
Published: (2021-01-01)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
by: Apsangikar P, et al.
Published: (2021-07-01)

Incidence of inflammatory reactions after intravitreal injection of a biosimilar of ranibizumab for the treatment of various retinal vascular conditions
by: Vivek Basavprabhu Wani, et al.
Published: (2023-01-01)

Physicochemical and Biological Stability Assessment of SB11 (Ranibizumab Biosimilar) Under Ambient and In-Use Storage for Intravitreal Administration
by: Peter K. Kaiser, et al.
Published: (2023-01-01)

SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR
by: A. N. Afanasyeva, et al.
Published: (2022-10-01)

Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence
by: Aditya S Kelkar, et al.
Published: (2021-01-01)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
by: Uta Kiltz, et al.
Published: (2022-08-01)

Efficacy and safety of rituximab biosimilar in refractory lupus
by: Nantakarn Pongtarakulpanit, et al.
Published: (2020-12-01)

The Clinical Implications of Nocebo Effects for Biosimilar Therapy
by: Luana Colloca, et al.
Published: (2019-11-01)

Insulin biosimilars in clinical practice
by: A. F. Verbovoy, et al.
Published: (2022-01-01)

The safety of biological preparations. Part 2. Safety issues of biosimilars
by: A. A. Soldatov, et al.
Published: (2018-02-01)

Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice
by: D. A. Kusevich, et al.
Published: (2022-06-01)

Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence
by: Chakraborty D, et al.
Published: (2023-04-01)

Late presentation of isolated spherophakia in an elderly woman with bilateral angle closure and cataract managed by lens extraction and retropupillary iris-claw lens implantation
by: Ajita Sasidharan, et al.
Published: (2022-01-01)

Commentary: Consensual ophthalmotonic reaction
by: Harsh Kumar, et al.
Published: (2023-01-01)

Pars plana implantation of glaucoma drainage devices - The way to succeed in refractory glaucoma
by: Harsh Kumar, et al.
Published: (2021-01-01)

Phacoemulsification without manual hydrodissection: “Passive-Hydro Phaco”
by: Mithun Thulasidas, et al.
Published: (2021-01-01)

Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy
by: Yaakub Azhany, et al.
Published: (2023-04-01)

Clinical effect of vitrectomy with intravitreal ranibizumab for diabetic retinopathy
by: Yun-Peng Wang, et al.
Published: (2014-07-01)

Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ranibizumab combined with retinal photocoagulation
by: Yan PS, et al.
Published: (2016-04-01)

Comment on Hernandez-Vasquez et al., a bibliometric analysis of the global research on biosimilars
by: Hillel P. Cohen
Published: (2018-12-01)

Biosimilars
by: Emel Bülbül Başkan
Published: (2022-04-01)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
by: Changkun Li, et al.
Published: (2023-12-01)

Update on the safety and bioequivalence of biosimilars – focus on enoxaparin
by: Jeske W, et al.
Published: (2013-06-01)

Safety of switching between rituximab biosimilars in onco-hematology
by: Silvana A. M. Urru, et al.
Published: (2021-03-01)

Biosimilars: State of Clinical and Regulatory Science
by: Agnes Victoria Klein, et al.
Published: (2018-01-01)